middle.news
How Arovella’s CLDN18.2 CAR-T Cells Could Transform Pancreatic Cancer Treatment
9:57am on Thursday 2nd of October, 2025 AEST
•
Biotechnology
Read Story
How Arovella’s CLDN18.2 CAR-T Cells Could Transform Pancreatic Cancer Treatment
9:57am on Thursday 2nd of October, 2025 AEST
Key Points
Novel CLDN18.2 CAR-T cells kill pancreatic cancer cells in vitro
Performance comparable to competitor’s CAR-T therapy under regulatory review in China
Plans to incorporate CAR into iNKT cells for enhanced solid tumour targeting
Upcoming in vivo studies in pancreatic and gastric cancer mouse models
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Arovella Therapeutics (ASX:ALA)
OPEN ARTICLE